Large hospital systems and pharmacy benefit managers have been taking advantage of a federal program for far too long, netting billions for themselves while access to care for low-income patients dwindles.
The program, known as the 340B Drug Pricing Program, requires pharmaceutical companies to offer discounted prescription medications to eligible health care entities that provide care to the specified 340B population – low-income patients not eligible for Medicaid or Medicare.